Bristol Myers Squibb on Friday introduced it agreed to acquire biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 for every share.
Karuna’s stock popped additional than 47% on the news Friday morning, hitting around $317 a share. Bristol Myers Squibb shares rose extra than 3%.
The deal will assistance develop Bristol Myers’ drug pipeline right after levels of competition from a generic offering brought on desire for the company’s blood most cancers drug Revlimid to tumble in its 3rd quarter.
The boards of administrators at the two Bristol Myers and Karuna unanimously accredited the acquisition, and it is anticipated to close in the initially 50 percent of 2024, according to a launch.
Karuna develops prescription drugs for patients living with neurological and psychiatric ailments. The company’s guide asset is an antipsychotic called KarXT, which is envisioned to serve as a cure for adults with schizophrenia beginning in late 2024, the release explained.
“There are large chances in neuroscience, and Karuna strengthens our posture and accelerates the expansion and diversification of our portfolio in the area. We count on KarXT to enrich our expansion by way of the late 2020s and into the future ten years,” Bristol Myers Squibb CEO Christopher Boerner stated in a statement.
KarXT is also getting evaluated as a achievable treatment method for Alzheimer’s sickness psychosis and a type of bipolar disorder, in accordance to the release. Karuna CEO Invoice Meury mentioned the company’s portfolio “provides progress in cure not noticed in several decades.”
“With Bristol Myers Squibb’s lengthy-standing abilities in building and commercializing medications on a worldwide scale and legacy in neuroscience, KarXT and the other belongings in our pipeline will be effectively-positioned to attain those people living with schizophrenia and Alzheimer’s condition psychosis,” he explained in a statement.
Citi and Gordon Dyal & Co recommended Bristol Myers on the deal, even though Goldman Sachs served as the special advisor for Karuna.
–CNBC’s Annika Kim Constantino contributed to this report
